Literature DB >> 24583361

Induction of human plasmablasts during infection with antibiotic-resistant nosocomial bacteria.

Victor I Band1, Chris Ibegbu2, Surinder Pal Kaur2, Stephanie M Cagle3, Ronald Trible4, Crystal L Jones1, Yun F Wang5, Colleen S Kraft4, Susan M Ray3, Jens Wrammert2, David S Weiss6.   

Abstract

OBJECTIVES: Nosocomial pathogens such as Acinetobacter baumannii are a growing public health threat, due in part to their increasing resistance to antibiotics. Since some strains are resistant to all available antibiotics, novel therapies are urgently needed. Plasmablasts are short-lived B cells found in the blood that can be collected and harnessed to produce therapeutic antibodies. We set out to determine whether plasmablasts are induced during infection with A. baumannii and other nosocomial pathogens.
METHODS: We obtained blood samples from patients infected with antibiotic-resistant nosocomial pathogens, and analysed their plasmablast response by flow cytometry.
RESULTS: We observed a strong induction of plasmablasts in patients with antibiotic-resistant A. baumannii infection. Furthermore, plasmablasts were also induced in response to other drug-resistant nosocomial pathogens.
CONCLUSIONS: These data suggest that plasmablasts may be broadly harnessed to develop therapeutic antibodies to combat otherwise untreatable antibiotic-resistant infections.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Acinetobacter baumannii; antibody therapy; nosocomial infections

Mesh:

Year:  2014        PMID: 24583361      PMCID: PMC4054983          DOI: 10.1093/jac/dku047

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

Review 1.  Competence and competition: the challenge of becoming a long-lived plasma cell.

Authors:  Andreas Radbruch; Gwendolin Muehlinghaus; Elke O Luger; Ayako Inamine; Kenneth G C Smith; Thomas Dörner; Falk Hiepe
Journal:  Nat Rev Immunol       Date:  2006-09-15       Impact factor: 53.106

2.  Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii.

Authors:  Michael J McConnell; Juan Domínguez-Herrera; Younes Smani; Rafael López-Rojas; Fernando Docobo-Pérez; Jerónimo Pachón
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

3.  Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.

Authors:  Anthony R White
Journal:  J Antimicrob Chemother       Date:  2011-06-23       Impact factor: 5.790

4.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Authors:  A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet
Journal:  Clin Microbiol Infect       Date:  2011-07-27       Impact factor: 8.067

5.  Infection control and prevention: a review of hospital-acquired infections and the economic implications.

Authors:  Deoine Reed; Sandra A Kemmerly
Journal:  Ochsner J       Date:  2009

6.  The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Ulrike MacDonald; Andrew D Cox; Frank St Michael; Evgeny V Vinogradov; Brad Spellberg; Nicole R Luke-Marshall; Anthony A Campagnari
Journal:  Infect Immun       Date:  2013-01-07       Impact factor: 3.441

7.  Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans.

Authors:  Jens Wrammert; Nattawat Onlamoon; Rama S Akondy; Guey C Perng; Korakot Polsrila; Anmol Chandele; Marcin Kwissa; Bali Pulendran; Patrick C Wilson; Orasri Wittawatmongkol; Sutee Yoksan; Nasikarn Angkasekwinai; Kovit Pattanapanyasat; Kulkanya Chokephaibulkit; Rafi Ahmed
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

Review 8.  Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.

Authors:  Leonard G Presta
Journal:  Adv Drug Deliv Rev       Date:  2006-05-23       Impact factor: 15.470

9.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus.

Authors:  Jens Wrammert; Kenneth Smith; Joe Miller; William A Langley; Kenneth Kokko; Christian Larsen; Nai-Ying Zheng; Israel Mays; Lori Garman; Christina Helms; Judith James; Gillian M Air; J Donald Capra; Rafi Ahmed; Patrick C Wilson
Journal:  Nature       Date:  2008-04-30       Impact factor: 49.962

10.  Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection.

Authors:  Guanpingshen Luo; Lin Lin; Ashraf S Ibrahim; Beverlie Baquir; Paul Pantapalangkoor; Robert A Bonomo; Yohei Doi; Mark D Adams; Thomas A Russo; Brad Spellberg
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

View more
  5 in total

Review 1.  The Antibody-Secreting Cell Response to Infection: Kinetics and Clinical Applications.

Authors:  Michael J Carter; Ruth M Mitchell; Patrick M Meyer Sauteur; Dominic F Kelly; Johannes Trück
Journal:  Front Immunol       Date:  2017-06-01       Impact factor: 7.561

2.  Vaccine-induced plasmablast responses in rhesus macaques: phenotypic characterization and a source for generating antigen-specific monoclonal antibodies.

Authors:  Eduardo L V Silveira; Sudhir P Kasturi; Yevgeniy Kovalenkov; Ata Ur Rasheed; Patryce Yeiser; Zarpheen S Jinnah; Traci H Legere; Bali Pulendran; Francois Villinger; Jens Wrammert
Journal:  J Immunol Methods       Date:  2014-11-08       Impact factor: 2.303

3.  Rapid laboratory diagnosis for respiratory infectious diseases by using MALDI-TOF mass spectrometry.

Authors:  Yun F Wayne Wang; Jianfeng Fu
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

4.  Cross-Reactive Bactericidal Antimeningococcal Antibodies Can Be Isolated From Convalescing Invasive Meningococcal Disease Patients Using Reverse Vaccinology 2.0.

Authors:  Fadil A Bidmos; Simon Nadel; Gavin R Screaton; J Simon Kroll; Paul R Langford
Journal:  Front Immunol       Date:  2018-07-16       Impact factor: 7.561

Review 5.  Bacterial Vaccine Antigen Discovery in the Reverse Vaccinology 2.0 Era: Progress and Challenges.

Authors:  Fadil A Bidmos; Sara Siris; Camilla A Gladstone; Paul R Langford
Journal:  Front Immunol       Date:  2018-10-08       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.